[en] 1. A lower target may be chosen in CKD patients with proteinuria but after individualized risk-benefit assessment. The price to pay is a need for a higher number of antiHTA drugs and a risk of more frequent side-effects.
2. Confirmation of a high BP level is necessary through out-of-the clinic BP measurement
In CKD, ABPM offers night-time BP information useful for CV and renal risk evaluation.
BP variability is a new point to be considered in the future.
Proteinuria but also other specific risk factors (Phosphate, anemia, inflammation,..) should be integrated in the management of hypertension in CKD
Disciplines :
Urology & nephrology
Author, co-author :
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
KDIGO – prise en charge de l’hypertension artérielle en dialyse
Alternative titles :
[en] How to manage BP in CKD patients (ND and D)
Publication date :
28 March 2013
Event name :
6e Symposium belge de Dialyse /6e Belgisch Dialyse Symposium
